Analysts Offer Predictions for Lantheus Holdings, Inc.’s Q2 2024 Earnings (NASDAQ:LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Investment analysts at B. Riley issued their Q2 2024 earnings per share (EPS) estimates for shares of Lantheus in a research note issued on Wednesday, June 26th. B. Riley analyst Y. Zhi anticipates that the medical equipment provider will post earnings of $1.67 per share for the quarter. B. Riley currently has a “Buy” rating and a $99.00 target price on the stock. The consensus estimate for Lantheus’ current full-year earnings is $6.46 per share. B. Riley also issued estimates for Lantheus’ Q3 2024 earnings at $1.49 EPS, Q4 2024 earnings at $1.52 EPS and FY2024 earnings at $6.18 EPS.

Several other equities analysts have also issued reports on LNTH. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Mizuho boosted their price objective on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. Finally, Truist Financial boosted their price objective on Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and an average price target of $99.17.

Lantheus Price Performance

Shares of LNTH opened at $78.50 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.55 and a current ratio of 4.84. The stock has a 50 day simple moving average of $78.03 and a 200 day simple moving average of $65.96. Lantheus has a 52-week low of $50.20 and a 52-week high of $91.81. The firm has a market capitalization of $5.44 billion, a PE ratio of 11.98 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.11. The company had revenue of $369.98 million during the quarter, compared to analyst estimates of $349.46 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%.

Insider Activity at Lantheus

In related news, Director Heinz Christoph Maeusli sold 18,373 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total value of $1,454,957.87. Following the sale, the director now owns 23,340 shares in the company, valued at approximately $1,848,294.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Daniel Niedzwiecki sold 12,873 shares of the stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the sale, the insider now directly owns 80,244 shares of the company’s stock, valued at approximately $6,408,285.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Heinz Christoph Maeusli sold 18,373 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total value of $1,454,957.87. Following the sale, the director now directly owns 23,340 shares in the company, valued at $1,848,294.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,269 shares of company stock worth $2,557,300. Company insiders own 2.10% of the company’s stock.

Institutional Trading of Lantheus

Several large investors have recently modified their holdings of LNTH. GAMMA Investing LLC boosted its stake in Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 208 shares in the last quarter. Tucker Asset Management LLC grew its holdings in shares of Lantheus by 239.0% during the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares during the last quarter. UMB Bank n.a. grew its holdings in shares of Lantheus by 161.4% during the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 247 shares during the last quarter. Principal Securities Inc. bought a new stake in shares of Lantheus during the fourth quarter worth about $28,000. Finally, Fidelis Capital Partners LLC bought a new stake in shares of Lantheus during the first quarter worth about $34,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.